FAQ on Lantern Pharma's AI Module for Accelerating Cancer Combination Therapies
Summary
What is the new AI module launched by Lantern Pharma?
Lantern Pharma has launched a new AI-powered module within its RADR(R) platform designed to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) for cancer treatment.
How does this AI module benefit cancer therapy development?
The module enables precise, biomarker-guided design of cancer treatment regimens, reducing development time and cost by up to one-third, as supported by a peer-reviewed analysis of 221 clinical trials.
What is the RADR(R) platform?
RADR(R) is Lantern Pharma’s proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to accelerate oncology drug discovery and development.
Can you provide an example of how this platform is being used?
Yes, the platform guided the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer combining LP-184 and olaparib.
What are the implications of this development for oncology?
This development could significantly accelerate the discovery and development of targeted cancer therapies, making treatments more efficient and cost-effective, with potential applications across multiple cancer indications.
How quickly can Lantern Pharma advance drug programs using this AI?
On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.
Where can I find more information about Lantern Pharma’s latest developments?
The latest news and updates relating to Lantern Pharma (LTRN) are available in the company’s newsroom at https://ibn.fm/LTRN.
Is Lantern Pharma exploring opportunities to scale this system?
Yes, Lantern is exploring licensing and commercialization opportunities to scale the system across oncology indications.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 107731